.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,459,561

« Back to Dashboard

Claims for Patent: 7,459,561

Title:N-substituted carbamoyloxyalkyl-azolium derivatives
Abstract: N-substituted carbamoyloxyalkyl-azolium derivatives which have antifungal activity and are useful for the treatment of fungal diseases.
Inventor(s): Fukuda; Hiroshi (Tokyo, JP), Hayase; Tadakatsu (Chigasaki, JP), Mizuguchi; Eisaku (Kamakura, JP), Shimma; Nobuo (Chigasaki, JP), Ohwada; Jun (Kamakura, JP), Oikawa; Nobuhiro (Kawasaki, JP), Sakaitani; Masahiro (Chigasaki, JP), Tsukazaki; Masao (Fujisawa, JP), Umeda; Isao (Yokohama, JP)
Assignee: Basilea Pharmaceutica AG (Basel, CH)
Application Number:11/504,299
Patent Claims: 1. A triazole compound consisting of an anion selected from pharmaceutically acceptable anions and a cation represented by the formula ##STR00037## wherein Q is a 1,2,4-triazole derivative selected from the group consisting of (2R, 3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-- triazol-1-yl)butan-2-ol, (2R, 3R)-3-[4-(4-cyanophenyl)thiazol-2-yl[-1-(1H-1,2,4-triazol-1-yl)-2-(2,4,5-- trifluorophenyl-butan-2-ol and (2R, 3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(3-fluorophenyl)-1-(1H-1,2,4-tria- zole-1-yl)-butan-2-ol, which triazole derivative is linked to the remainder of the said cation by a nitrogen in the triazole; R.sup.1 is hydrogen or alkyl; R.sup.2 is hydrogen, alkyl, alkylcarbonyloxyalkyl, alkoxycarbonyl, alkylcarbonyl, mono- or dialkylaminoalkylcarbonyloxyalkyl; R.sup.3 is pyridin-2-yl or substituted pyridin-2-yl, wherein R.sup.3 is substituted pyridin-2-yl, said cation is represented by the formula ##STR00038## wherein ##STR00039## is pyridin-2-yl; R.sup.4 and R.sup.5 are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, alkyloxycarbonyl, cyano, trifluoromethyl, trifluoromethoxy, nitro, aminosulfonyl and sulfo; and R.sup.6 is selected from the group consisting of hydroxy, alkoxycarbonylalkylamino, alkoxycarbonylamino, amino, alkylamino, alkylcarbonyloxy, alkoxycarbonylalkylaminoalkylcarbonyloxy alkoxycarbonylamino-alkylcarbonyloxy, alkylaminoalkylcarbonyloxy, aminoalkylcarbonyloxy, alkylcarbonylamino, alkylcarbonylalkylamino, acyloxy, acylamino, and acylalkylamino, wherein said acyl is a hydrolizable radical; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein R.sup.4 and R.sup.5 are independently selected from the group consisting of hydrogen, halogen and alkoxy.

3. The compound of claim 2 wherein R.sup.4 and R.sup.5 are hydrogen.

4. The compound of claim 3 wherein R.sup.6 is alkylaminoalkylcarbonyloxy.

5. The compound of claim 4 wherein R.sup.1 is hydrogen or alkyl.

6. The compound of claim 5 wherein R.sup.2 is alkyl.

7. The compound of claim 6, wherein Q is (2R, 3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-- triazol-1-yl)butan-2-ol.

8. The compound of claim 1, wherein Q is (2R, 3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-- triazol-1-yl)butan-2-ol, R.sup.1 is hydrogen or alkyl, R.sup.2 is alkyl, R.sup.4 and R.sup.5 are hydrogen, R.sup.6 is alkylaminoalkylcarbonyloxy and said pharmaceutically acceptable anion is an anion of a pharmaceutically acceptable acid.

9. The compound of claim 1, wherein said cation is (2R, 3R)-1-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl]carbamoylox- y]ethyl-1-2-(2,4-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazol-2-y- l]butyl]-1H-[1,2,4]triazol-4-ium.

10. The compound of claim 1, wherein said compound is 1-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl]carbamoyloxy]et- hyl-1-[(2R,3R)-2-(2,4-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazo- l-2-yl ]butyl]-1H-[1,2,4]triazol-4-ium chloride or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, wherein said cation is 1-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl]carbamoyloxy]et- hyl-1[(2R,3R)-2-(2,4,5-trifluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thia- zol-2-yl]butyl]-1H-[1,2,4]triazol-4-ium.

12. The compound of claim 1, wherein said compound is 1-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2]carbamoyloxy]ethyl- -1-[(2R,3R)-2-(2,4,5-trifluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazo- l-2-yl]butyl]-1H-[1,2,4]triazol-4-ium chloride or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 wherein said cation is 1-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl]carbamoyloxy]et- hyl-1-[(2R,3R)-2-(3-fluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazol-2-- yl]butyl]-1H-[1,2,4]triazol-4-ium.

14. The compound of claim 1, wherein said compound is 1-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl]carbamoyloxy]et- hyl-1-[(2R,3R)-2-(3-fluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazol-2-- yl]butyl]-1H-[1,2,4]triazol-4-ium chloride or a pharmaceutically acceptable salt thereof.

15. A triazole compound consisting of an anion selected from pharmaceutically acceptable anions and a cation represented by the formula ##STR00040## wherein ##STR00041## is pyridin-2-yl; Q is a (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl)]-2-(2,5-difluorophenyl)-1-(1H-2- ,4-triazol-1-yl)-butan-2-ol moiety which is linked to the remainder of the cation by a nitrogen in the triazole; R.sup.1 is hydrogen or alkyl; R.sup.2 is hydrogen, alkyl, alkylcarbonyloxyalkyl, alkoxycarbonyl, alkylcarbonyl, mono- or dialkylaminoalkylcarbonyloxyalkyl; R.sup.4 and R.sup.5 are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, alkyloxycarbonyl, cyano, trifluoromethyl, trifluoromethoxy, nitro, aminosulfonyl, alkylaminocarboyloxyalkyl, sulfo, alkylcarbonyloxyalkyl and aminoalkylcarbonyloxyalkyl; R.sup.6 is alkylaminoalkylcarbonyloxy, or aminoalkylcarbonyloxy; or a pharmaceutically acceptable salt thereof.

16. The triazole compound of claim 15 wherein R.sup.4 and R.sup.5 are independently selected from the group consisting of hydrogen, halogen and alkoxy.

17. The triazole compound of claim 16 wherein R.sup.4 and R.sup.5 are hydrogen.

18. The triazole compound of claim 17 wherein R.sup.2 is alkyl.

19. The triazole compound of claim 15 wherein said cation is 1-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl]carbamoyloxy]et- hyl-1-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazo- l-2-yl]butyl]-1H-[1,2,4]triazol-4-ium.

20. The triazole compound of claim 15 wherein said cation is 1-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl]carbamoyloxy]et- hyl-1-[(2R,3R)-2-(2,5-difluorophenyl-2-hydroxy-3-[4-(4-cyanophenyl)thiazol- -2-yl]butyl]-1H-[1,2,4]triazol-4-ium and said anion is an anion of a pharmaceutically acceptable inorganic acid.

21. The triazole compound of claims 20 wherein said anion is a chloride, bromide or sulfate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc